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There are few reported methods for combining two or three different imaging 
dyes, metals, or dye-metal combinations, followed by the conjugation of a disease-
targeting group to enable the use a given imaging system for multiple imaging 
applications.  Previously, peptides have been used as scaffolds for dyes and metals used 
in diagnostic techniques such as optical molecular imaging (OMI), positron emission 
tomography (PET), and magnetic resonance imaging (MRI).  The aim of this project was 
to reassemble peptide-based imaging agents through a modular method by coupling 
together modules comprised of amino acids with imaging agents attached to their side 
chains to form “imaging peptides,” followed by attaching a cancer-targeting group in the 
final step. This new modular approach for the synthesis of a diverse set of targeted 
molecular imaging agents (TMIAs) was optimized and exemplified by the synthesis of 
dual modal PET-MRI, dual OMI-MRI and dual metal (di-gadolinium for MRI), and the 
partial synthesis of a tri-modal OMI-PET-MRI agent.  The dual modal imaging peptides 
were conjugated through a linker to targeting groups for lung cancer (A549 cells) and 
prostate cancer (PSMA positive C4-2) cells.  In addition to imaging applications for early 
detection, active surveillance, image guided biopsies and surgery, this modular approach 
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Frequently Used Solvents 
ACN: acetonitrile 
 AmAc: Ammonium Acetate, used as an aqueous buffer 
DCM: dichloromethane 
 DI H2O: deionized water, 18mΩ 
DMF: n,n-dimethylformamide 
DMSO: dimethyl sulfoxide 




Frequently Used Reagents and Compounds 
 BuAm: n-butylamine 
 DEA: diethylamine 
 DIPEA or DIPA: diisopropylethylamine 
 dLys, dK: the unnatural isomer of lysine 
 DOTA: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
 Lys, K: lysine, a natural amino acid 
 NMM: n-methylmorpholine 
 NMP: N-methyl-2-pyrrolidone 
 TEA: triethylamine 
 TFA: tetrafluoroacetic acid 
 
Other Instrumentation 
 HPLC-MS: high-pressure liquid chromatography and mass spectrometry 
 HPLC-prep: preparative high-pressure liquid chromatography 
 HRMS: high resolution mass spectrometry 
 NMR: nuclear magnetic resonance 
 SPE: solid-phase extraction  
 UPLC-MS: ultra-performance liquid chromatography and mass spectrometry 
 
Molecular Imaging Terms 
 CA: contrast agent for MRI use 
 MRI: magnetic resonance imaging 
 PET: positron emission tomography 
 TCA: targeted contrast agent for MRI use 
 TMIA: targeted molecular imaging agent 
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 Cancer refers to a group of diseases that are characterized by the uncontrolled 
growth and spread of abnormal cells.  If left untreated, cancer is likely to result in death. 
More than 1.7 million new cancer cases were expected to be diagnosed in 2019 in the 
U.S. and approximately 606,880 Americans were expected to die of cancer in 2019.1   
This translates to roughly 1660 deaths per day, making cancer the second most common 
cause of death in the United States, exceeded only by heart disease.  Although our 
understanding and knowledge of cancer and its treatment methods continues to grow2, the 
number of new cancer cases per year is also growing.3  Due to the ever-growing societal 
impact of cancer, improving cancer detection and treatment methods remains to be an 
important scientific research endeavor.	
There are many different types of cancer.  The commonality between all the 
different types is that cancer cells divide without stopping and begin to spread into 
surrounding tissues in the body.4  Cancer can start in almost any of the trillions of cells in 
the body, but usually begins in the more vulnerable tissue of the organs.  When cancer 
develops, the typical orderly process of healthy cells growth breaks down. This causes 
old or damaged cells to survive when they should die and uncontrollably replicate into 
new cells.  These extra cells will divide without stopping and form tumors. This makes 
cancer a genetic disease, since it causes changes in the DNA that, in turn, controls the 
way our cells function. Due to the nature of cancer and the way that it grows as its cells 
divide, it can sometimes be an extremely difficult or impossible disease to treat. 
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There are many different types of treatment methods used to combat cancer.  Each 
method has varying levels of side-effects and the treatment method utilized typically 
depends on the type of cancer and how severe it is.5  Three of the most common 
treatment methods are surgery, radiation therapy, and chemotherapy. In surgery, a 
surgeon physically removes cancer from the body.  Radiation uses high doses of radiation 
to irradiate cancer cells and to shrink tumors.  Chemotherapy uses potent drugs to kill 
cancer cells.5  In most cases, each of these treatment methods have a significant physical 
toll on the human body and are not always successful in eliminating the disease.  In 
addition to these three most common and well-known methods, there are other methods 
of treatment including immunotherapy and photodynamic therapy (PDT).6,7  
Combinations of these different treatment methods are often used to increase the success 
and decrease the likelihood that the cancer returns. 	
Screening for cancer is an extremely important medical diagnostic tool.  This 
refers to testing individuals who have no symptoms or early symptoms of cancer.  Early 
detection has proved to reduce mortality from cancers of the colon and rectum, breast, 
uterine cervix, prostate, and lung.8,9  Early treatment of the disease is the most effective 
way to increase the chance of survival as it makes treatment methods more effective.  
Unfortunately, without early detection, most cancer treatments occur at a relatively 
advanced stage.  Because cancer cells can quickly form tumors and spread if untreated, 
early diagnosis is important, to allow medical professionals to promptly begin treatment 
of the cancer. 
  Molecular imaging is a widely-used detection method that can be used in the 
diagnosis of cancer and provides the greatest hope for curing cancer.  By targeting 
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specific biomarkers in cancer cells, molecular imaging that utilizes targeted molecular 
imaging agents (TMIAs) may vastly increase the effectiveness and success of cancer 
detection.  The goal of this research project was to develop a synthetic route that other 
researchers and manufacturers can utilize to provide a wide variety of TMIAs.  This new, 
easier and robust method could provide tailor-made TMIAs that could potentially be used 
in the diagnosis of many types of cancer with the overall goal of improving cancer 
detection which would ultimately decrease the mortality rate due to cancer.  	
1.2. Molecular Imaging Methods Relevant to Cancer Detection 
  Currently, there are limited methods used to screen for cancer.  Methods can be 
invasive, such as a biopsy, where cell tissue is physically removed from a person’s body 
to test for the presence of the disease.  In contrast, non-invasive methods such as 
molecular imaging prove to be more desirable in screening for cancer as they do not 
involve the surgical removal of tissue in the body which can be painful and carries risk of 
infection and other factors.10   
There is conventional imaging with no contrast agents or non-targeted agents used 
in imaging methods such as PET and MRI.  While these may detect large tumors, these 
methods are not ideal for the detection of cancer in its early stages.   
The most common molecular imaging methods which employ contrast agents 
used in the detection and diagnosis of cancer are MRI, PET, computed tomography (CT), 
optical molecular imaging (OMI), also known as fluorescence imaging) ultrasound 
imaging, and x-ray imaging.11–13 The integration or fusion of two imaging methods 
together can lead to a more effective imaging method. Instruments are currently available 
for two modes of imaging.   For example, a combined PET/CT scanner is one of the most 
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frequently used instruments in the field of oncology.14  In a PET/CT, images are obtained 
separately and combined together using digital processing.  This combination of 
instrumentation provides more information than one image and can provide higher image 
quality since there are two complimentary imaging methods being fused together.  
 Precise imaging is essential in determining the best method of treating the cancer 
and molecular imaging methods allow radiologists to precisely locate cancerous cells and 
determine how far cancer has spread. Although imaging methods can be accurate in their 
imaging of the tissues inside the body, it is sometimes difficult to distinguish healthy 
tissue from cancerous tissue cells.  For cancer detection to be accurate, it is important that 
molecular imaging methods are reliable and can consistently provide an accurate picture 
of the cancer in the body. 
1.3. Targeted Molecular Imaging Agents  
In order for cells to be imaged with a high signal-to-background (signal-to-noise) 
ratio, targeted imaging agents can be used to increase the visibility of the diseased cells.15  
This allows cancerous cells to be more easily differentiated from healthy cells, even when 
there is a small amount of diseased cells.  Targeted molecular imaging agents (TMIAs) 
are the best means of providing better contrast of the disease to improve the overall 
quality of the image.9,16    
Targeting peptides have been previously coupled with imaging agents (e.g. 
radiometals and fluorophores) using different chemical techniques in order to create 
TMIAs.15 These imaging peptides, when coupled with separate cancer-targeting moieties, 
proved to be extremely effective in the early detection and diagnosis of cancer.  This is 
due to the fact that cancer targeting compounds are able to target cancer cells selectively 
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and with high affinity.17  Since the imaging peptides are connected to the cancer-targeting 
moiety, the imaging agents will be in a high concentration due to specific localization in 
the cancerous cells only.  When appropriate molecular imaging techniques are used to 
detect the imaging agents, only the cancerous cells become illuminated and are thus more 
accurately distinguished compared to the background, neighboring tissues, or other 
artifacts in the image.   
Figure 1 shows a schematic of how a TMIA is able to selectively target a receptor 
on a tumor cell membrane using the receptor targeting biomolecule.  Since the receptor 
targeting biomolecule is attached to an imaging agent (the radioactive 64Cu atom in this 
case), the cancer can be detected using PET.  This image with illuminated cancer cells is 
seen in the top left of Figure 1. 
 
Figure 1. Schematic of a TMIA being used in PET showing a targeting biomolecule attached to a 
PET imaging agent binding to a  tumor receptor on the membrane of a cancer 18 
Reprinted with permission from Shokeen, M.; Anderson, C. J. Molecular Imaging of  Cancer with Copper-64 Radiopharmaceuticals 
and Positron Emission Tomography (PET). Acc Chem Res 2009, 42 (7), 832–841. https://doi.org/10.1021/ar800255q. Copyright 2009 
American Chemical Society. 
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1.4. Cancer Targeting Groups 
 TMIAs would not possibly be able to target cancer without having affinity for 
cancer cells.  In the early years of molecular imaging, scientists found that there are 
certain peptides that target biomarkers found in cancerous cells.   The most widely used 
peptide for this purpose for many years was the cyclic peptide c(RGDyK).  This  peptide 
contains the RGD peptide sequence, known to have a strong affinity for the avb3 integrin 
that is overexpressed in many different cases of cancer, such as melanoma, ovarian, lung, 
and breast cancer.19   Integrin proteins are critical for self-adhesion of cells in cancerous 
tissue and it is also a biomarker in plaques that form in blood vessels due to 
atherosclerosis.  The chemical structure of c(RGDyK) is shown in Figure 2. 
 
Figure 2. c(RGDyK), a well-known cancer targeting peptide 
Due to the preferential binding of the RGD peptide to cancerous cells, it proves to 
be a promising method for the delivery of anticancer drugs and contrast agents for cancer 
therapy and diagnosis.19  This peptide was the first targeting agent that was used by the 
Schmitthenner Molecular Imaging Lab (MIL) at Rochester Institute of Technology 
(Figure 3), where c(RGDyK) in red was directly bound to the Cy 5.5 dye (in green) and 
used for confocal fluorescence microscopy (CFM) of A549 lung cancer cells. 
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Figure 3. c(RGDyK)-Cy 5.5 TMIA (left) and CFM image of lung cancer cells targeted by the 
TMIA (right). There are about ten cells shown in this image, with the heart shaped cell in the 
middle as an example.  The red color is a result of targeting by the TMIA, which is engulfed and 
accumulates in each cell by the process of endocytosis. 
 A second, more recently discovered cancer targeting compound of interest in our 
molecular imaging laboratory is the peptidomimetic inhibitor N[N-[(S)-1,3-
dicarboxypropyl]carbamoyl]-(S)-lysine, which is abbreviated as DCL.  DCL targets the 
prostate-specific membrane antigen (PSMA) receptor which is overly expressed in 
aggressive forms of prostate cancer (PCa). DCL was designed after the three dimensional 
X-ray structure of was determined, as an inhibitor of the active site. This makes DCL 
extremely effective in the targeting PCa and in wide use  currently.20,21  A method for the 
synthesis of this urea-based moiety shown in Figure 4, to be used in targeting PCa has 
been developed in our group as well.22   
 
Figure 4. DCL urea-based PSMA inhibitor 
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  Prior to the breakthrough of small-molecule TMIAs in 2008, the main targeting 
agent used in clinical diagnosis of PCa by PET was the antibody based ProstaScint®.23  
ProstaScint® presented challenges and was unreliable due to low plasma clearance, long 
circulation times which resulted in high-background signal, limited tissue penetration, 
and restriction of molecular binding to the intracellular domain of cancer cells.22,24   
When creating TMIAs, it is important to consider the wide variety of different 
cancer targeting agents that can be used in the molecule that is being synthesized.  Our 
group currently uses a modular synthetic approach, where the imaging agents (dyes, 
radioactive metals, etc.) are created first and the cancer agent is added to the molecule in 
the final steps of the synthesis.  This provides an enormous advantage as it makes it 
possible to combine a given modular imaging system with a variety of different targeting 
agents to be used for a wide variety of different cancer types.   
1.5. Relevant Imaging Agents 
 There are many different imaging methods that are currently utilized in the 
detection and examination of cancer cells including MRI, CT, PET, and CFM.  Each 
method visualizes cancer cells with varying levels of effectiveness (e.g. contrast of the 
cells).  The imaging agents discussed in this chapter are not a comprehensive review of 
all imaging agents, but are a summary of those types of agents that are most prominent in 
our research. Each imaging method uses different physical parameters to obtain an image 
and each has unique advantages or disadvantages over other methods. By combining 
imaging modalities, we can often combine aspects that are advantageous.  By combining 
agents for each of those modalities into one molecule we can provide further 
improvements to molecular imaging methods.       
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1.5.1. MRI Imaging Agents 
 MRI functions by detecting energy released from protons in the body as they 
align with the magnetic field of the instrument then relax to their ground states.25  MRI 
imaging (contrast) agents are either ferromagnetic or paramagnetic agents.  These agents 
work by shortening the relaxation times of the nuclei within the body.  MRI is sensitive 
to different relaxation times (T1 and T2).  The T1 relaxation time (spin-lattice relaxation 
time) is a measure of how quickly the net magnetization vector recovers back into the 
field of the MRI magnet.  The T2 relaxation time (spin-spin relaxation time) refers to the 
time required for the decay of the magnetization that is transverse to the field of the MRI 
magnet.  These relaxation times are the basis for which an MRI instrument makes 
measurements.  Gadolinium(III) (Gd3+)  may enhance those relaxation times and is 
therefore  one of the most common and widely used paramagnetic contrast agents used in 
clinical and pre-clinical (animal studies) MRI.26   
While gadolinium has proved to be an extremely effective contrast agent in MRI, 
the metallic form of gadolinium can have toxic effects if it is released in the body.  It is 
therefore necessary to use gadolinium, which is chelated to an organic structure which 
can facilitate it’s bioavailability in circulation and excretion.  This can be achieved by 
using chelating groups such as dodecane tetraacetic acid (DOTA), a well-known 
complexing agent that has medical applications as a contrast agent and in cancer 
treatment.  DOTA is highly effective as chelating gadolinium ions and other metals used 
in radioactive molecular imaging modalities such as PET.  The structure of DOTA is 
shown in Figure 5. 
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Figure 5.  DOTA, a well-known complexing agent used in cancer imaging 
In addition to chelation, a second means of increasing safety is to reduce the 
concentration of gadolinium per injection.   The use of a targeted imaging agent enables 
the contrast agent to concentrate only in the area of interest.  This allows for the use of far 
less gadolinium-based agent, leading to much lower concentrations in the body.   
Furthermore, there have been studies showing that gadolinium is not removed at 
wastewater treatment plants, allowing the toxic metal to be released into the aquatic 
environment. Through the use of targeted imaging agents, far less gadolinium will be 
required resulting in far less gadolinium in the waste stream.27  
Thus, in addition to increased brightness and quality of the image provided by a 
targeted DOTA-chelated gadolinium contrast agent, the safety of patients is enhanced 
along with the quality of downstream aquatic environments.   
As alternatives to the use of gadolinium, different metals or inorganic 
nanoparticles compatible with MRI can be used to increase the sensitivity of the image.  
These have been reviewed by Hyon Bin Na et al. who summarizes the progress of 
inorganic MRI contrast agents.28  However, gadolinium contrasts agents continue as the 
overwhelming majority of agents used in the clinical setting.27 
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1.5.2. PET Imaging Agents 
 PET detects gamma rays emitted by a positron-emitting radionuclide to create 
images.  Unlike MRI, which uses a contrast agent to enhance an image, PET is dependent 
on an exogenous agent and requires the injection of a radioactive molecule into the 
patient in order to obtain an image.18  Although an imaging agent is required, in PET an 
extremely small amount of material is needed (on the nmol to pmol scale), which causes 
a minimal pharmacological effect on the subject.   
 PET uses radiopharmaceuticals labelled with positron emitting radionuclides 
(such as 11C, 13N, 15O, and 18F) to obtain the image.14  Radionuclides, which are atoms 
with an unstable nucleus, can easily be incorporated into organic molecules and used in 
the body for PET imaging.  In the past, 18F has been widely used as a radionuclide for 
PET in oncology in the form of fluoro-2-deoxy-glucose (18F-FDG).29  However, 
difficulties in the synthesis and the short lifespan of the isotope has encouraged imaging 
scientists to find alternative radionuclides.   
A radioactive isotope of copper, 64Cu, has been found to have longer lasting decay 
characteristics that allow for PET imaging and targeted radiotherapy of cancer.30  The 
well-known coordination chemistry of copper allows for it to be used in a wide range of 
systems, such as DOTA chelates, that can be linked to peptides and other biologically 
relevant compounds.  
Radioactive gallium,  68Ga is another radionucleotide used in PET imaging.  Since 
radioactive metals are not used in our lab for safety purposes, we use the stable isotopes 
of each respective metal in our work.  Since the metals’ size is not greatly affected 
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between the radionucleotide and stable isotopes, it is assumed that the reactions with the 
radioactive isotopes would be similar.   
 The radioactive half-life of common radionucleotides that can be used in PET 
imaging are given in Table 1.  The radioactive half-life is defined as the time for half of 
the radioactive nuclei to undergo radioactive decay.  Consequently, after one half-life, 
there will be one half of the original sample remaining.  For this reason, longer half-lives 
are desired as they will give imaging agents more time to accumulate in the desired area 
in the body leading to a more resolved image. 
Table 1. Radioactive half-lives of common radionucleotides used in PET31 
Isotope Half-life 
11C 20.364 minutes 
13N 9.965 minutes 
15O 122.24 seconds 
18F 109.77 minutes 
64Cu 12.701 hours 
68Ga 67.71 hours 
 
1.5.3. OMI and CFM Imaging Agents 
 Optical molecular imaging is a broad term that encompasses many techniques 
which are based on the fluorescence of dyes.  In molecular imaging these are most often 
in the near infrared (NIR) region of the electromagnetic spectrum.   In our research, we 
rely on confocal fluorescence microscopy (CFM) in order to prove that a TMIA binds 
specifically to the particular cancer cell lines that we are targeting.    
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CFM is a microscopic technique that provides 3D optical resolution of the 
subject.  In CFM, white light is used to image all cells and cell components within those 
such as the mitochondria and cell walls which may be visualized with great clarity.  
Along with white light, a powerful light beam from a laser is used to excite a fluorescent 
dye to produce an image of the cell.32  In molecular imaging the dyes used are generally 
absorb and emit light in the near infrared (NIR) region of the spectrum.  One 
disadvantage to this technique compared to the other techniques mentioned (MRI and 
PET) is that it can only be used on the surface of the skin or with invasive surgery, where 
cells are removed from the body. 
Cyanine 5.5 NHS ester (Cy 5.5) is a reactive dye that has previously been used in 
the labeling of amino-groups in peptides, proteins, and oligionucleotides.33  Cy 5.5 is a 
far-red and near-infrared emitting dye which is ideal for fluorescence measurements.  It 
can be used in CFM as to produce an enhanced image in a different wavelength channel 
than the white light.  When overlaid, thee two channels will show the entire cell 
(generally in black and white) with a fused image of those cells and regions of cells to 
which the TMIA has targeted and bound.   The chemical structure of a tri-sulfonated form 
of Cy 5.5 3S, synthesized by our published methods, is shown in Figure 6.34    
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Figure 6. Cy 5.5 NHS Ester Structure  
1.5.4. Dual-modal Imaging Agents 
 Imaging agents are generally utilized in single modal imaging using their 
respective imaging techniques such as ferromagnetic and paramagnetic metals for MRI, 
radionuclides for PET, and dyes for CFM.  To improve imaging, these imaging agents 
can also be combined to make dual-modal imaging agents.  Dual-modal imaging agents 
combine two different imaging agents into one single molecule. This allows two different 
imaging methods to be used simultaneously using specialized instrumentation.  Dual-
modal imaging is a very powerful method that allows for two imaging techniques to 
complement each other and provide much more information than one single method. 
Pairing modalities such as in PET/CT and PET/MRI in current clinical 
applications allow for improved diagnostic sensitivity and specificity in the detection of 
diseased regions in the body.32 Single photon emission computed tomography 
(SPECT)/CT and  MRI/Optical (fluorescence) are two other dual-modal imaging methods 
that are used clinically.9   In addition to clinical applications, the largest use in current 
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research for dual modal agents is in preclinical research in which animals such as mice 
are utilized to test and develop imaging methods and imaging agents.   
While it is possible to use two separate imaging agents and achieve enhancements 
in each by using dual techniques, there is a distinct advantage of using a single targeted 
probe containing imaging agents for each modality.  When using two different single 
modal agents there can be questions regarding their equivalence of reaching the binding 
site.  For example, a metal containing agent may have a different uptake, circulation half- 
life and biodistribution than a dye containing agent.  Likewise, metabolism and clearance 
are a challenge for imaging agents just as they are for drugs.   
By combining these into a single agent, such ambiguity and uncertainly is avoided 
and this assures that the circulation, targeting kinetics and pharmacodynamics for each 
motif is identical.  This is a main advantage of dual-modal imaging agents.  A general 
schematic of a peptide-based dual-modal TMIA is given in Figure 7. 
 
Figure 7. General schematic of a dual-modal TMIA 
In Figure 7, the imaging agents are connected together through a peptide by 
attaching a chelated metal or a dye to the side chain of lysine modules, then connecting 
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those modules using our patented method.35  Theoretically, these imaging agents would 
provide two different imaging methods.  For example, one imaging agent may contain a 
paramagnetic gadolinium atom that would be suitable as a MRI and one may contain a 
radioactive copper-64 atom suitable for PET.  This would allow the molecule to be used 
for PET/MRI in the detection of cancer, assuming that an appropriate cancer targeting 
agent was used.   
 The images that are created in dual-modal imaging are typically more enhanced 
and provide more information than the single modal imaging methods.  Because of this, 
the imaging methods are said to be complimentary to each other.  Figure 8 shows an 
image of a 60-year-old patient’s brain with glioblastoma multiforme.  The image was 
obtained using simultaneous PET/MRI acquisition.36 
 
Figure 8. PET/MRI scan of patient with glioblastoma multiforme36 
Reprinted with permission from  PET/MRI in cancer patients: first experiences and vision from Copenhagen | SpringerLink 
https://link.springer.com/article/10.1007%2Fs10334-012-0357-0. Copyright 2012 Springer. 
 
In the Figure 8, the MRI contrast agent is not targeted, but is able to provide 
detailed morphological (spatial) information to the radiologist.  The PET agent is targeted 
and thus provides the functional information (what is it, or is it a tumor?)  However, PET 
images are typically very blurry compared to MRI enables determination of exact 
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location (where is it, exactly?). Thus, PET and MRI are complementing each other in 
dual PET-MRI imaging.  Because of the complementary benefit from both agents, dual-
modal imaging agents for cancer detection has been the focus of many research programs 
with the ultimate goal of improving the sensitivity and contrast of molecular imaging. 
1.5.5. Comparison of MRI, PET, and OMI 
 In molecular imaging methods, the combination of different imaging modalities is 
important since each modality has its own set of advantages and disadvantages.37  
Complimenting imaging methods with the dual of dual-modal imaging agents adds value 
over single-modal imaging. While two different TMIAs could be used in some 
circumstances, there is uncertainty whether they would have the same bioavailability in 
circulation, or the same concentration at different time points based on the kinetics of 
their metabolism and excretion.  By combining two different modalities into a single 
molecule, this uncertainty is removed. 
 While OMI utilizes NIR dyes to increase penetration through body tissue over 
visible dyes, the depth of imaging is only between 2-5 mm.  The main use of OMI is in 
cellular research using in vitro studies which use microscopy and other commercial 
instruments. In preclinical research, OMI is often used in mice as the depth of penetration 
is suitable to study the binding of agents to grafted tumors that are actively growing.  
However, as a result of the depth of penetration, clinical use for detection is largely 
restricted to melanoma and other types of skin cancer. 
 Although there are issue with the depth of penetration, there has been a large 
surge in both research and translation to human patients in the area of light directed 
surgery including the use of NIR-based TMIAs for guiding the removal of cancer tissue 
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during surgery.38  Beyond this, OMI is not useful for detecting cancer in internal organs 
and it is not possible to image the human brain using OMI due to the lack of penetration..  
Another drawback to OMI is non-microscopic animal images can be blurry, making OMI 
a low-resolution imaging method. 
 Unlike OMI, MRI has excellent depth of penetration and is considered a whole 
body imaging method.  This includes its ability to image the brain, which is encased in 
bone, and other organs deep within the body.  A second advantage is that MRI provides 
excellent spatial resolution, and it is the only technique that can differentiate soft tissues.  
It can provide contrast, for example, between a tumor and the organ in which the tumor is 
located.  The main disadvantage is that MRI is not very sensitive compared to OMI and 
PET.  A high concentration of gadolinium-based contrast agents is required.  Targeting 
the agent can improve the contrast ability. 
 As a complement to both MRI and OMI, PET imaging (which uses targeted 
radioactive metals) has excellent depth penetration.  Like MRI, PET can be a whole body 
technique (including imaging of the brain).  PET also has excellent sensitivity as it only 
takes a small concentration of the imaging agent to be detected.  One disadvantage of 
PET is that the resolution is considered low and, like OMI, yields blurry images on the 
macro-scale.  It is therefore advantageous to combine PET, with its excellent sensitivity, 
with MRI, which has great resolution. 
1.6. Previous Literature Research in Imaging Agents 
 In the past, DOTA has been used in the synthesis of imaging agents due to its 
strong chelating characteristics which make it beneficial in carrying and holding metals.  
Chelation of a metal, such as 64Cu has proved to be extremely useful in PET imaging.  In 
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early, pioneering work, Zhang and colleagues demonstrated a method where DOTA was 
conjugated to the antibody TRC105 and labeled with 64Cu for PET imaging.39  The 
scheme for this reaction is given in Figure 9. 
 
Figure 9. DOTA conjugation with TRC10539 
Figure 9 shows how the TRC105 antibody can be coupled to DOTA, which would 
go on to chelate copper-64.  In the reaction, the NHS ester acts as a leaving group and 
reacts with the primary amine of the TRC105.  Since TRC105 is a specific monoclonal 
antibody, it can be used as a marker for tumor angiogenesis and thus the DOTA-TRC105 
is a TMIA in PET for detection of cancerous tumors.39   
 DOTA can be used in a different fashion, where multiple DOTA complexes are 
added to a single antibody.  Cai and colleagues demonstrated a method where multiple 
DOTA complexes were added to a Cetuximab molecule, which is an antibody that targets 
cancer.40  This was done for PET imaging and copper-64 was used as the radioactive 
label.  Although this method proved to be successful in the clinical evaluation of patients 
using PET, the molecule could only be used in PET imaging.  The presence of multiple 
DOTA groups in this application did not allow for multiple imaging methods to be used 
since all the DOTA complexes were chelating copper-64 atoms.  The current goal of our 
group reaches beyond the work of Cai et al., into the realm of multimodal imaging. 
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1.6.1. Previous Literature Research in Dual-modal Imaging Agents 
 As mentioned, imaging methods can be used simultaneously on specialized 
instrumentation by incorporating another type of imaging.  Multi-modal imaging agents 
emerged in the 1990s, when dual modal imaging methods such as PET/CT came to 
clinical use.9,41  In 2013, Suchy and colleagues presented a method that used DOTA-
derived heterometallic complexes as potential MRI/PET(SPECT) molecular probes.42  
This method used Gd3+ as an MRI agent and the cold (non-radioactive) isotopes of Cu2+, 
Ga3+, and In3+ as potential PET or SPECT agents.  The molecules that were made in this 
project were synthesized using the well-known “click” chemistry method.43  The 
structure of one of the bimodal  MRI/PET(SPECT) molecular imaging agents that was 
synthesized in this work shown in Figure 10.  It is noted that this agent is not targeted.   
 
 
Figure 10. Structure of a DOTA-derived chelator coupled with a porphyrin moiety via a peptide 
bond to form a non-targeted molecular imaging agent42 
Reprinted with permission from  Suchý, M.; Bartha, R.; Hudson, R. H. E. “Click” Chemistry toward Bis(DOTA-Derived) 
Heterometallic Complexes: Potential Bimodal MRI/PET(SPECT) Molecular Imaging Probes. RSC Adv. 2013, 3 (10), 3249–3259. 
https://doi.org/10.1039/C3RA23260C. Copyright 2013 Royal Society of Chemistry. 
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In Figure 10, it can be seen that the DOTA moiety is chelating a gadolinium atom 
(for MRI) and the porphyrin moiety contains a copper atom (for PET).  The use of both 
of these metals in the same molecule yields a bimodal imaging agent.  Although the 
authors did not use a radioactive isotope of copper, which is the only form that would 
work with PET, it is suggested that their synthetic method would be similar with the 
radioactive isotope.   
Similar to our modular approach, both the MRI and PET chelating complexes are 
built separately and are combined in a later step the synthetic method used by Suchy et 
al. Each metal containing framework built before the metal is added to the complex.  This 
is due to the fact that once the metal is added, it serves as a protecting group for the 
complex and the complex then becomes unreactive.  Although this presented a useful 
methodology to be used in potential MRI/PET(SPECT) molecular probes, the authors did 
not utilize a cancer-targeting group in their synthesis.  Thus, these agents are not targeted 
molecular imaging agents.  
 In a related project, Gros et al. present a method to create bimodal contrast agents 
for medical imaging, mostly notably in PET/MRI.10  Their methodology was relatively 
similar to the method that Suchy et al. used.  However, instead of incorporating the metal 
atoms in the imaging moieties prior to their combination, metalation was done in the last 
steps of the synthesis.  Figure 11 shows the addition into the bimodal contrast agent of 
the atoms Gd for MRI and Cu for PET . 
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Figure 11. Metalation of the imaging agent in the final steps10 
Reprinted with permission from  Gros, C. P.; Eggenspiller, A.; Nonat, A.; Barbe, J.-M.; Denat, F. New Potential Bimodal Imaging 
Contrast Agents Based on DOTA-like and Porphyrin Macrocycles. Med. Chem. Commun. 2011, 2 (2), 119–125. 
https://doi.org/10.1039/C0MD00205D. Copyright 2011 Royal Society of Chemistry. 
 
In this method, the synthesis of the desired PET/MRI imaging agent is based on 
the  selectivity and affinity of the metal chelating groups.  Gros et al. demonstrated  that 
the gadolinium atom has a higher affinity for the DOTA cavity (as it is shown in the 
figure) whereas copper matched better for the tetravalent pyrrole based chelator.10  As in 
the prior dual modal method, there is no targeting in this scheme.   
 In 2008, Overoye-Chan et al. presented a method in which a fibrin specific 
gadolinium-based MRI contrast agent was made for the detection of thrombus (EP-
2104R).44  The synthetic approach for creating this multi-Gd containing molecule is 
shown in Figure 12. 
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Figure 12. Final steps in the synthesis of EP-2104R, a Gd-based MRI contrast agent44 
Reprinted with permission from  Overoye-Chan, K.; Koerner, S.; Looby, R. J.; Kolodziej, A. F.; Zech, S. G.; Deng, Q.; Chasse, J. M.; 
McMurry, T. J.; Caravan, P. EP-2104R: A Fibrin-Specific Gadolinium-Based MRI Contrast Agent for Detection of Thrombus. J. Am. 
Chem. Soc. 2008, 130 (18), 6025–6039. https://doi.org/10.1021/ja800834y. Copyright 2008 American Chemical Society. 
 
This molecule was further studied by another group at Harvard Medical School.45  
As it can be seen, the molecule in Figure 12 is not a bimodal imaging agent due to the 
fact that the only imaging moieties contained within the molecule are the DOTA-chelated 
gadolinium atoms, which are useful in MRI.  The goal of the group at Harvard was to 
image thrombus using both MRI and PET simultaneously.  To achieve this, the MRI 
agent EP-2104R was improved upon by partially exchanging the gadolinium metal atoms 
from copper-64, which is a suitable PET radionucleotide.  Figure 13 shows the synthetic 
approach that was used. 
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Figure 13. Partial exchange of gadolinium for copper-64 in EP-2104R44 
Reprinted with permission from  Overoye-Chan, K.; Koerner, S.; Looby, R. J.; Kolodziej, A. F.; Zech, S. G.; Deng, Q.; Chasse, J. M.; 
McMurry, T. J.; Caravan, P. EP-2104R: A Fibrin-Specific Gadolinium-Based MRI Contrast Agent for Detection of Thrombus. J. Am. 
Chem. Soc. 2008, 130 (18), 6025–6039. https://doi.org/10.1021/ja800834y. Copyright 2008 American Chemical Society. 
 
The PET-MRI probe did enhance the images of thrombus in rats. However, in 
terms of synthesis, the approach is flawed in that the partial metal exchange method that 
was used in this approach is not selective and leads to a mixture of dual metal species 
with an average reported ration of 5% radiolabel.  The result is not a single compound as 
there is no way to exactly control the percentage of the gadolinium atoms that are 
exchanged.  
In the pharmaceutical industry, when a drug is translated to the clinic and 
approved by the Food and Drug Administration (FDA), the process is faster when the 
drug is a single molecule that can be purified and characterized completely by 
spectroscopy.  Likewise, in the development of targeted imaging agents it is always 
preferable to produce a single, purified and well characterized compound.   This presents 
a challenge that our group has worked to improve.  
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 In 2015, Kumar and coworkers at the University of Texas Southwestern Medical 
Center (Dallas, Texas) reported a versatile dendritic molecule that can be used for 
developing dual-modality imaging agents.37  The molecules created are dendritic 
structures with a NOTA core and multiple copies of DOTA groups branching out (Figure 
14). 
 
Figure 14. Dual-modal molecular imaging agent design by Kumar et al.37 
Reprinted with permission from  Kumar, A.; Zhang, S.; Hao, G.; Hassan, G.; Ramezani, S.; Sagiyama, K.; Lo, S.-T.; Takahashi, M.; 
Sherry, A. D.; Öz, O. K.; Kovacs, Z.; Sun, X. Molecular Platform for Design and Synthesis of Targeted Dual-Modality Imaging 
Probes. Bioconjug. Chem. 2015, 26 (3), 549–558. https://doi.org/10.1021/acs.bioconjchem.5b00028. Copyright 2015 American 
Chemical Society. 
 
 In an elegant solution to dual modal imaging, this molecule is capable of selective 
chelation to gallium and gadolinium based on the different sizes of the NOTA and DOTA 
cores.  As outlined in Figure 14, the NOTA core is selective for 67,68 Ga3+, which is useful 
for SPECT and PET, and the DOTA moieties are selective for Gd3+, which is useful for 
MRI.  Out of the many imaging agents cited in literature, this dual-modal imaging 
approach is possibly the most similar to the molecules synthesized in our lab at RIT.  
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Functionally and structurally, the molecule has similar characteristics. However, our 
group’s molecules are both smaller and have a simpler synthetic approach. 
1.7. Dual-Modal Imaging Instrumentation 
 In order for dual-modal molecular imaging agents to be most useful, appropriate 
dual-modal imaging instrumentation must be available.  MILabs currently markets an 
imaging module for pre-clinical imaging (of animals) called the U-OI that couples 
fluorescence imaging with PET, SPECT, and/or CT for preclinical imaging.46  Although 
all of these imaging platforms are not housed in the same instrument, the imaging module 
is designed to have a single animal holder that ensures its position does not change in 
order to facilitate the exact fusion of images.  Animals are typically anesthetized and 
immobilized during imaging procedures so this is entirely possible.  A picture of the 
instrument from the manufacturer’s website is shown in Figure 15. 
 
Figure 15. Duet Optical Imaging module, U-OI from MILabs46 
The first MILabs imager is a standalone instrument that is capable of 
bioluminescence, fluorescence, and Chrenkov imaging (optical imaging of radiotracers), 
and this was then integrated with additional imaging platforms such as PET, SPECT, for 
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dual modal imaging (OMI-PET or CT) with an optional CT built into the latter to provide 
true tri-modal imaging (OMI/PET-SPECT/CT).   
There are no current dual or tri-modal imaging systems involving fluorescence or 
optical molecular imaging as this modality is now largely viewed as mostly useful for 
directing real time surgical procedures such as light-directed surgery (LDS) in human 
patients as a single modal process.     
 There are, however, instruments that combine PET and MRI for simultaneous 
acquisition.  Dual PET instrumentation was first introduced into the clinic in 2008 and 
since that time has been reviewed as a significant investment opportunity.47–50  To date, a 
number of companies have designed and manufactured preclinical and clinical hybrid 
imaging systems for PET-MRI.  Some of these instruments are also offered with CT to 
provide tri-modal imaging.  Bruker manufactures a system that combines MRI and PET 
into an instrument for preclinical imaging of mice, the PET/MR 3T.51  This instrument 
allows for scientists to test their dual-modal imaging agents in the early stages of 
development before moving onto clinical trials.  MedisoUSA also makes a preclinical 
imaging platform known as the nanoScan Family.52  This instrument combines PET and 
SPECT with CT and MRI to allow for nine different imaging combinations.   
 A number of additional companies including Siemens are ramping up the design 
and manufacturing phase or PET-MRI instrumentation, clearly showing a robust growth 
rate in preclinical and clinical dual modal imaging systems.  However, it is also clearly 
apparent that the development of dual modal targeted probes, in particular TMIAs for 
PET-MRI, lags the development in instrumentation.  This represents a driving force for 
the research presented here.  In particular, there are no general methods for the synthesis 
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of dual modal probes in which a given dual-modal imaging system can be tethered to a 
wide variety of targeting agents.  It is anticipated that more dual-modal, and possibly tri-
modal, imaging instrumentation will be developed which will give rise to a pressing need 
for dual- and tri-modal TMIAs for a wide variety of cancer types.   
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2. Modular Method for Multi-Modal Agents 
 Our group has developed a modular method to synthesize peptide-based imaging 
agents that is based on the principles of peptide chemistry.22,35  DOTA-chelated metals 
and imaging dyes are synthesized separately from each other and separate from the 
cancer-targeting module. These various imaging groups, used in imaging methods such 
as MRI, PET, CFM, etc., are placed on the side chains of amino acids early in the 
synthesis.  Using amino acids allows the use of well-known peptide coupling methods to 
connect different imaging moieties to cancer-targeting agents.  In this approach, lysine, 
shown in Figure 16, is the amino acid that was used as the basis for each module due to 
the primary amine on its side chain.  The primary amine can be easily reacted with 
imaging modules, to produce stable imaging modules.   
 
Figure 16. Structure of L-lysine, the amino acid commonly used in our targeted molecular 
imaging agents 
Due to the nature of the well-known features and reactions of peptides, the design 
of our imaging agents is simple and the synthesis is practical.  There are many advantages 
to using peptides over other organic molecules.  Peptides are small and compact, 
typically ranging from 1,000 to 3,000 g/mol, which is relatively small for an imaging 
agent.  The intermediate imaging peptides and final TMIAs can be readily purified by LC 
and characterized by LC-Mass Spectroscopy.  This enables our group to focus effort on 
synthesizing new, improved dyes, developing new TMIAs and less time on developing 
and troubleshooting new chemical reactions. 
 30 
2.1. Modular Synthetic Approach 
 Our group’s approach utilizes preformed amino acid-based imaging moieties that 
are eventually combined with a cancer-targeting agent in the final steps.  The amino acid 
moieties are connected to each other using peptide coupling chemistry which forms an 
amide bond (peptide bond) from the amine terminus (on the left of each amino acid) to 
carbon terminus of the in-coming amino acid. A generalized schematic of our group’s 
modular peptide synthetic approach is outlined (Figure 17).  
 
Figure 17. General schematic of the modular peptide synthesis of TMIAs 
The two imaging agents being connected to each other in this scheme are: a NIR 
dye and chelated-metal.  These imaging modules (which can be seen as reactants on the 
left side of the arrow) are typically synthesized and purified in-house using different 
methodologies, depending on the component.  It can be seen that both of the imaging 
modules in this reaction contain a lysine-based backbone, which allows for the different 
components to be connected using peptide coupling methods.   
Also shown in Figure 17 is an example of a linker that is used in the synthesis.  
Linkers are commonly used in our modular synthetic method to connect the cancer-
targeting component of the molecule to the imaging component of the molecule.  This 
allows the targeting group to be put on during the last step in the synthesis.   
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A color-coded example of a molecule created in this project using this modular 
synthetic methodology is shown in Figure 18.  The colors in this figure match the colors 
of the components of the TMIA shown in Figure 17. 
 
Figure 18. Color-coded structure of final TMIA, c(RGDyK)-SMCC-dK(Cy5.5)-K(DOTA-Gd)-NH2 
A key aspect of the modular synthesis is to apply a given imaging system to a 
variety of targeting systems.  To exemplify this, a similar color-coded example of a 
TMIA created previously in our group using similar modular synthetic methodology, but 
employing the PCa PSMA-targeting group DCL as described earlier, with a linker 










Figure 19.  Color-coded structure of final TMIA, DCL-DSS- dK(Cy 5.5)-K(DOTA-Gd)-NH2 
In Figure 19, from the left, the prostate cancer-targeting DCL group is connected 
to a lysine module which carries a NIR imaging dye through a DSS linker.  This is, in 
turn, connected to a second lysine module carrying a DOTA-chelated gadolinium atom.  
Each of these components serve a purpose: the DCL targets the cancer, the linker 
connects the targeting agent to the imaging modules.  The NIRF dye is useful in optical 
imaging, and the gadolinium is useful in MRI.  When connected together, these four 
components combine their separate purposes to form a powerful targeted imaging agent. 
 There are many different methods that can be used to combine amino acids and 
form larger molecules, including linear and convergent synthetic methods.  These 
methods each have different orders in which the molecule is built.  Our group typically 
uses linear synthetic method to build peptides, although convergent methods sometimes 
lead to a better yield. 
2.1.1. Linear Synthetic Approach  
 In a linear synthetic method, the desired molecule is synthesized through a 
sequence where the product of one reaction is the reactant in the next reaction.  In terms 
DCL targeting group
 
DSS Linker MRI AgentDOTA-Gd 
NIR dye Cy5.5
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of the imaging agents that we work with, this method builds the peptide based modules 
from the right to left.  Polypeptides are created by forming peptide bonds, which involves 
the nitrogen (N-terminus) of the first amino acid being bonded to the carbon (C-terminus) 
of the second.  A schematic of the linear synthetic method of the TMIAs created in our 
group is given in Figure 20. 
 
Figure 20. General schematic showing linear synthetic method of TMIAs, linker added in a 
separate linker step 
2.1.2. Convergent Synthetic Approach  
 In a convergent synthetic method, fragments of the desired molecule are 
synthesized separately and brought together at a later stage in the synthesis to form the 
target molecule.  A schematic for convergent synthesis involving the TMIAs created in 
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Figure 21. General schematic showing convergent synthetic method of TMIAs, linker part of 
targeting module 
 In our syntheses of TMIAs, each method (convergent and linear) has shown 
advantages and disadvantages depending on the chemistry involved for each particular 
TMIA that has been synthesized.  This will be described in further detail.    
2.2. Identification and Analysis of TMIAs and Intermediates  
 In this study, reactions were monitored via HPLC-MS instrumentation (Waters) 
or UPLC -MS (Shimadzu).  This allows for confirmation of the molecule when the 
calculated m/z = [M+H]+, [M+2H]2+ and/or [M+3H]3+ peak(s) are present in the positive 
electrospray (ES+) spectra.  In some instances, for example when sulfonated dyes are 
present, these are seen in negative electrospray (ES-) as m/z = [M-H]-, [M-2H]2-, and/or 
[M-3H]3-. Key intermediates and final products that were first characterized in our lab 


















Chemical Sciences for high resolution mass spectroscopy (ESI-HRMS).  The masses in 
these HRMS are typically accurate to four or five decimal places and can be used to 
confidently report that the desired molecule was synthesized.  
 In most cases, important intermediates and final products were purified by 
preparative reverse phase chromatography and assaying collected eluant fractions by 
analytical HPLC-MS. Fractions containing pure products (90-100% purity in single 
wavelength chromatograms at 264 nm for compounds containing Fmoc group, and 90% 
+ purity in total ion chromatograms for compounds with no chromophore groups) were 
pooled, concentrated by rotary evaporation under a vacuum, then lyophilized (freeze-
dried) and yields determined from the resultant mass obtained.   
 TMIA’s synthesized by these methods have been tested for their binding and 
selectivity by confocal microscopy in the past, including imaging the TMIA shown in 
Figure 18.  However, this testing has not taken place (due to the unfortunate passing of 
our collaborator in Biology, Dr. Irene Evans) on any of the compounds in this new work.   
However, our group has begun a collaboration with Dr. Maureen Ferran from RIT’s 
GSOLS and we also collaborate with Roswell Park Cancer Center, and the University of 
Rochester.  Several of the TMIAs described have been sent to these new collaborators.  
These collaborations allow us to test our imaging agents both in vivo and in vitro. 
An example of the targeting that is achieved by a TMIA synthesized earlier by 
students in our lab is shown in Figure 22.  In this study A549 lung cancer cells were 
cultured, stained with the dual modal TMIA shown in Figure 18, (prepared earlier by 
students in our lab)  and imaged by confocal fluorescence microscopy.  As described 
earlier, the targeting agent c(RGDyK) targets the integrin receptors.  The targeting agent 
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clearly binds well to the cancer cells as shown by the red imaging.  The blue imaging is 
created by a stain called NucBlu that specifically stains the nuclei of cells. 
In addition, the process of endocytosis can be clearly seen.  This is a mechanism 
where by xenophobic molecules such as the TMIA, after binding to the receptor, can be 
engulfed into the cytoplasm of the cells.  The receptor site is regenerated very rapidly, 
and addition agents may enter the cell.  It is our speculation that this can act as an 
amplification scheme to increase the signal.  It can be easily deduced then, that since this 
is a dual modal agent, that the gadolinium moiety is also contained within the cell and, as 
it is covalently linked through the modular system to the dye, that the gadolinium must 
therefore also be present in the cells. 
 
 
Figure 22. Confocal fluorescence microscopy (CFM) of three A549 lung cancer cells targeted by 
the TMIA, c(RGDyK)-SMCC-dK(Cy5.5)-K(DOTA-Gd)-NH2 shown in Figure 18. There are about 
three  cells shown in this image.  The red color is a result of targeting by the TMIA, which is 
engulfed and accumulates in each cell by the process of endocytosis. The blue color is a result of 
staining of the cells by NucBlu, a widely used dye that stains only cell nuclei 
 Similar to the targeting of A549 cancer cells by c(RGDyK) assayed by CFM, our 
collaborators in GSOLS under the direction of Dr. Evans have achieved many images of 
prostate cancer (PCa) cells including an aggressive type called C4-2 which express 
PSMA (PSMA+) and compared these with atype of PCa cells that are indolent called 
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PC3 cells that express low levels of PSMA (PSMA-).  An example of a TMIA for this is 
B2, synthesized earlier in the Molecular Imaging Laboratory at RIT.  The structure is 
shown in Figure 23, followed by images of the B2-targeted C4-2 cells in Figure 24 (on 
















Figure 24. Left: Image of about ten C42 (PSMA+) prostate cancer cells illuminated by the TMIA 
B-2, DCL-DSS-Lys(Cy5.5). The red color is a result of targeting by the TMIA, which is engulfed 
and accumulates in each cell by the process of endocytosis.  Middle:  Same image of cells in 
which the  nuclei are lit up with NucBlue. Right: About 20 PC3 (PSMA-) cells in a control 
experiment which were treated with the same concentration of TMIA, showing weak binding. 
In Figure 24 as noted, the TMIA binds to the (PSMA+) prostate cancer cells and 
is engulfed by a process known as endocytosis,  illuminating the cells in red. The middle 
image are the same cells with a blue channel turned on that shows staining by NucBlu 
which specifically illuminates the cell nuclei.  On the right are the control PC-3 (PSMA-) 
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cells which show very little binding as the expression of PSMA is not elevated in that cell 
line.  A similar structure was previously reported by the Pomper group at Johns Hopkins 
who similarly showed successful targeting by several similar NIR dye-based TMIAs 
using DCL-DSS as the targeting motif.20,53  
It is important to note that while we have not tested the PCa targeted imaging 
agents prepared in this work by CFM, based on the successful targeting of the dual modal 
agent using c(RGDyK) that matched earlier successful targeting of single modal agents 
both in our lab and in the literature53, it may be predicted that dual modal agents 
containing both the dye used in Figures 23 and 24 with the same cell lines will also 
produce successful targeting and imaging .    
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3. Results and Discussion 
3.1. Synthetic Approach to Metal-Containing Imaging Modules 
This project focused largely on metal-containing modules that were designed to 
be used in MRI and PET.  The reaction method that is used to synthesize these metal-
containing modules was carried out using a one-pot synthetic approach, which was 
optimized by a fellow lab member, Dana Murphy Soika.  The method used to create these 
modules is similar regardless of the metal used.  Scheme 1 is the reaction scheme 
outlining a “one-pot” synthetic method that was used to create the metal-containing 
puzzle pieces used in this research project.22 
 
Scheme 1. General one-pot synthesis for F-K(M1-DOTA)-R imaging modules, R=NH2 or OH and 
M1=Gd or La 
 There are several conditions that were important to optimize yield.  When running 
this reaction, DOTA was first dissolved in a dilute solution of DMF and heated to 70°C.  
This starting solution should be dilute to discourage any possible di- and tri-substituted 
DOTA groups, since mono-substitution is desired.  It was found that heating the reaction 
mixture aids with solvation of the DOTA, which also maximizes yield of the desired 
DMF, 70 to 25 °C
i) NMM, TBTU
ii) Fmoc-(L or D)-Lys-R
iii) Gd(OAc)3 or La(NO3)3 
Fmoc-(L or D)-Lys-R (1-3) 
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product.  Once the DOTA is dissolved in the reaction mixture, NMM is added to create a 
basic reaction mixture that allows activation of DOTA by TBTU.  TBTU, a peptide 
coupling reagent, is added at a rate of 0.3 mL/min to also favor mono-substitution on the 
DOTA.  The lysine is then also added at this slow rate to favor the preferred product.  
The metal (Gd or La) is added in the final step and is chelated by the DOTA molecules.  
This method is extremely versatile, as it can be used to make many different imaging 
modules.  In Scheme 1, the R-group is either -OH or -NH2 and M1 is either Gd or La in 
the scope of this project.  This makes the method useful for both MRI and PET imaging 
modules. However, this method could theoretically be used for a countless number of 
different metal and amino acid combinations. 
3.2. Fmoc Deprotections 
The imaging modules discussed in Section 3.1 are made with an amino acid 
(lysine) that can be reacted with from the N-terminus or the C-terminus.22  A 
fluorenylmethyloxycarbonyl (Fmoc) group is the most commonly used protecting group 
in peptide synthesis.  It is used to protect the N-terminus of an amino acid from any 
unwanted side reactions during other synthetic steps.  A deprotection step to remove the 
Fmoc group must be carried out in order to further couple other molecules to the N-
terminus amine.  Scheme 2 is a reaction scheme showing a Fmoc deprotection reaction of 
a metal-containing imaging module introduced in Section 3.1.  
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Scheme 2. General schematic showing simple Fmoc deprotection procedure, F-K(M1-DOTA)-
NH2 to H-K(M1-DOTA)-NH2 
 As can be seen in Scheme 2, treatment of the Fmoc group with diethylamine in an 
organic solvent successfully removes the group with yields nearing 100%.  After the 
Fmoc group is removed, the N-terminus of the molecule is ready to further react with 
another molecule.  Figure 25 shows the mechanism for the Fmoc deprotection.  
 




3.3. NHS Ester Synthesis 
N-Hydroxysuccinimide (NHS) is a reagent that is commonly used for activating 
acids to prepare them for coupling to amines such as the alpha N-terminus amine when 
elongating a peptide chain.  The structure of NHS is given (Figure 26). 
 
Figure 26. NHS Structure 
NHS is frequently used in biological chemistry to activate carboxylic acids so 
they are able to react with amines to form an amide.  In this project, the NHS ester was 
commonly utilized to couple two different modules together.  This includes coupling 
dyes to peptide side chains, coupling peptide modules together, and coupling imaging 
modules to targeting modules and/or linkers to targeting modules.  Scheme 3 is a reaction 
scheme showing creation of an NHS ester using TSTU  and the reaction with an amine in 
a subsequent reaction as outlined in a paper by Wilchek et al.54  . 
 
Scheme 3. General reaction scheme showing formation of NHS ester in first reaction and 
coupling in second reaction (R and R’ are different modules) 
3.4. Synthesis of Dual-Modal TMIA for Prostate Cancer Using OMI-MRI 
While single modal agents based on targeting by DCL have been synthesized, and 
one dual modal agent for OMI-PET55, we have found no dual modal agents for OMI-MRI 
or PET-MRI that utilize DCL. Thus, it seems appropriate to demonstrate our modular 





modal TMIA was created for the purpose of imaging prostate cancer using both OMI and 
MRI.  This was achieved by pairing a Cy 5.5 dye module (for OMI) with a gadolinium-
based imaging module (for MRI) to the prostate cancer targeting agent DCL.  Following 
the protocol outlined in Section 3.2, the Fmoc group was removed from the F-K(Gd-
DOTA)-NH2  (2) module to create H-K(Gd-DOTA)-NH2 (5), which would be ready to 
react with the NHS ester of the Cy 5.5 dye module.  Cy 5.5 3S was synthesized using the 
procedure published by previous group members Damien Dobson et al.34  The NHS ester 
of the Cy 5.5 3S dye was created using the methodology outlined in Section 3.3.  The 
specific reaction scheme showing the formation of the Cy 5.5 NHS ester can be seen in 
Scheme 4.  Scheme 4 also shows the Cy 5.5 NHS ester being coupled to the Fmoc 
protected lysine  to form the desired dye-based imaging module.   
 







Using the same methodology presented Section 3.3, the NHS ester of the F-
dK(Cy5.5 3S)-OH (4) molecule was created, then reacted with a second module.  The 
NHS ester, also referred to as the oxysuccinimidyl (OSu) group, F-dK(Cy5.5 3S)-Osu, 
was reacted with deprotected gadolinium module for MRI, H-K(Gd-DOTA)-NH2 (5), as 
outlined in Scheme 5 to create the dual-modal imaging module for OMI-MRI.   
 
Scheme 5. Synthesis of Dual-Modal Imaging Module, F-dK(Cy5.5 3S)-K(Gd-DOTA)-NH2 (6) 
The Fmoc group of this dual-modal molecule was removed using the method 
outlined in Section 3.2 to create a reactive form of the peptide.  From here, the molecule 
could be reacted with a cancer targeting group in order to create the desired TMIA.   
In order to complete the synthesis of the dual modal TMIA for PCa, a convergent 
method, developed by Damien Dobson and published earlier by former group members, 
was utilized.22   
In this convergent method, the DCL was first connected to the linker DSS. This 






imaging system for OMI-MRI.   The reaction in which the targeting module containing 
the linker was connected to the dual-modal imaging module is shown in Scheme 6. 
 
Scheme 6. Synthesis of Final Prostate Cancer Targeting Dual-Modal TMIA, DCL-DSS-dK(Cy5.5 
3S)-K(Gd-DOTA)-NH2 (8) 
Since the linker and targeting group were added as one module in this step, this 
presents a convergent synthetic approach.  Our group has found that using the convergent 
approach most often increases the yield of the TMIA in the final synthetic steps.   
The product shown in Scheme 6 has been dubbed as G3 in our Molecular Imaging 
Lab and a sample has been supplied to Dr. Ferran in RIT’s GSOLS and to Dr. Nastiuk of 
Roswell Park for evaluation in both the CFM imaging and MRI of prostate cancer.      
All of the intermediates and final products (4-8) described in Section 3.4 were 
purified and assayed as described in Section 2.2.  The details of their synthesis, 






3.5. Synthesis of Dual-Modal TMIAs for PET-MRI 
Two pseudo PET-MRI agents were next created using a similar methodology as 
the OMI-PET agent described in Section 3.4   In these examples, a lanthanum atom was 
used as a placeholder for radioactive atoms that could be used in PET. As we are unable 
to use radioactive metals in research at RIT (for safety concerns), the nonradioactive form 
of these atoms were used in our lab. It is expected that the radioactive forms of these 
metals would behave chemically similar—and allow for PET functionality.  In order to 
make a dual-modal imaging agent for PET-MRI, the challenge was to couple two 
different metal containing modules together, and then to differentiate these based on the 
stability of one metal over the other metal in dilute acid.   
Using the same method outlined in Section 3.1, F-dK(La-DOTA)-OH (1) and F-
K(Gd-DOTA)-NH2 (2) were synthesized. These modules were coupled together after 
removing the Fmoc group from the gadolinium-containing molecule and creating the 
NHS ester of the lanthanum-containing molecule. It is important to note that the 
lanthanum-containing module contained an alpha carboxylic acid functional group for the 
specific purpose of coupling this to the gadolinium module.  The order of these molecules 
could have been flipped if the lanthanum piece had an amide functional group at the end 
and the gadolinium piece had a carboxylic acid group at the end.  As the DOTA-Gd 
chelate is a very robust complex we typically used that as our C-terminus starting 
module.  The dipeptide imaging agent was created as shown in Scheme 7. 
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Scheme 7. Synthesis of Dual-Modal Imaging Molecule for PET-MRI, F-dK(La-DOTA)-K(Gd-
DOTA)-NH2 (9) 
After the product in Scheme 7 was synthesized, the Fmoc group was removed 
using the deprotection reaction outlined in Section 3.2 in order to prepare it for 
conjugation to the cancer targeting group.  In this case, instead of the DCL-urea based 
targeting group used for the TMIA in Section 3.4, this the cancer-targeting c(RGDyK) 
was employed.  Although a different cancer-targeting group was used, the same DSS 
linker was used for this TMIA as it was discovered to be easier to react than SMCC, a 
linker used previously in our lab.  As in the case of the targeting module DCL-DSS, the 
targeting group was connected to c(RGDyK) before it was added to the dual-modal 
imaging molecule. As with the novelty of DCL-DSS, we believe this to be the first 







Scheme 8. Coupling Reaction of c(RGDyK) cancer targeting group and DSS linker 
In order to discourage the di-substituted product in Scheme 8, the c(RGDyK) was 
added dropwise to the reaction mixture.  This technique was found to sufficiently produce 
the mono-substituted product. Once this module was created, it was ready for reaction 
with the dual-modal imaging molecule previously described and shown in Scheme 7.   
 After the dual-modal imaging module (in Scheme 7) and the c(RGDyK)-DSS (11)  
(in Scheme 8) pieces were synthesized and appropriately purified—and the Fmoc group 
was removed from the dual-modal imaging module—the two groups could be combined 
to form the final scaffold for the desired TMIAs.  The term “scaffold” is used since the 
only difference between the desired TMIA and the scaffold is replacing the lanthanum 
metal placeholder atom with a gallium or copper atom.  This convergent synthesis of the 
penultimate final TMIA is shown in Scheme 9.  Kelsea Jones, a former group member, 
was able to successfully synthesize the compound in Scheme 9.  However, Kelsea was 







Scheme 9. Coupling of targeting group and linker, c(RGDyK)-DSS (11), with dual-modal 
imaging agent to form TMIA scaffold, c(RGDyK)-DSS-dK(La-DOTA)-K(Gd-DOTA)-NH2 (12) 
The transmetalation procedure shown in Scheme 10 takes advantage of previous 
studies in our laboratory where we learned that lanthanum is labile in dilute TFA (0.2 M), 
whereas gadolinium robust and is not labile under these conditions.  This provides a 
convenient method which is based on the stability of Gd-DOTA coordination bonds 
which remain intact while the La-DOTA coordination bonds are labile and broken, 
allowing for the lanthanum to be transmetalated.   This can occur in a one-step method, 
but we find it more effective to use a two-step method that is further described in the 








Scheme 10. Transmetalation of lanthanum atom with potential PET imaging atoms to create final 
TMIA, c(RGDyK)-DSS-dK(M-DOTA)-K(Gd-DOTA)-NH2, M=Cu (13) or Ga (14) 
 
All of the intermediates and final products (9-14) described in Section 3.5 were 
purified and assayed as described in Section 2.2.  The details of their synthesis, 
purification and identification by LC-MS and HRMS are in in Appendix I.    
 The use of the placeholder metal and the synthetic feature involving a final 
transmetalation to metal atom useful for PET imaging provides an important advantage of 
the modular method.  It is important to consider that the radioactive forms of the metals 
copper and gallium, may be avoided in the entire synthesis and that this step could be 
performed in the clinic or animal research lab.  As the non-radioactive placeholder metal 
would not be vulnerable to radioactive decay with short half-lives, it could be stored for 
long periods of time and a portion of it be exchanged to the radioactive metal when 
needed.  In addition, it could be transported safely to remote testing sites with no 
concerns.  The transmetalation would be performed easily by the radiologist or their team 
right before the TMIA was about to be used in the healthcare setting. 
H2O
CuSO4 or Ga(NO3)3, TFA
(12) (13), M=Cu 
(14), M=Ga 
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3.6. Synthesis of Dual-Gadolinium Targeted Contrast Agent for MRI 
The contrast of an MRI imaging can be increased with increasing molarity 
contrast agent.  A widely used method of achieving this is to place two or more 
gadoliniums in a single agent.  Among many reports in the literature is a study involving 
similar DCL-DSS targeted agents by the Pomper group at Johns Hopkins.   Apart from 
this study, there have been few reports of contrast agents for MRI which rely on DCL or 
other PSMA inhibitors as targeting moieties.  We therefore wished to demonstrate that 
the modular method developed in the MIL lab would be a useful means of creating dual 
or even multi-Gd TMIAs.22  
A dual-gadolinium MRI contrast agent was therefore created by coupling two   
Gd imaging molecules, F-dK(Gd-DOTA)-OH (3) and F-K(Gd-DOTA)-NH2 (2), which 
were synthesized using the same method outlined in Section 3.1. These modules were 
coupled together after removing the Fmoc group from the amide molecule and creating 
the NHS ester of the carboxylic acid molecule, as outlined in Scheme 11. 
 







 After the dual-modal imaging agent in Scheme 11 was synthesized, the Fmoc 
group was removed using the deprotection reaction outlined in Section 3.2.  At this point, 
the molecule could be reacted with a cancer-targeting group.  Similar to the synthesis 
presented in Section 3.5, c(RGDyK)-DSS (11) was made in a coupling reaction 
(identically to Scheme 8) and was attempted to be added to the dual-gadolinium imaging 
module.  After monitoring the reaction it was determined that the c(RGDyK)-DSS was 
not reacting with the dual-gadolinium module.  This may have been due to the fact that 
the NHS ester of the DSS had been hydrolyzed from residual water.  To overcome this, a 
linear synthesis was attempted in which the DSS and c(RGDyK) were added separately.  
Using this method, which is outlined in Scheme 12, the final dual-gadolinium contrast 
agent was created. 
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Scheme 12. Coupling of linker, then targeting group in two separate steps to create final TMIA, 
c(RGDyK)-DSS-dK(Gd-DOTA)-K(Gd-DOTA)-NH2 (17), using a linear synthetic approach 
In Scheme 12, it can be seen that a linear synthetic method was used in the 
synthesis of this TMIA.  Although the convergent approach described earlier was 
attempted the c(RGDyK)-DSS did not effectively couple to the dual-gadolinium module 
using the convergent synthetic method.  This was attributed to the low solubility of the 
di-gadolinium product which required heating, which led to degradation of the sensitive 
NHS ester on the DSS moiety.  In contrast, the two-step linear method of adding the DSS 
first was more effective, as the DSS itself added solubility to the otherwise sparingly 







All of the intermediates and final products (15-17) described in Section 3.6 were 
purified and assayed as described in Section 2.2.  The details of their synthesis, 
purification and identification by LC-MS and HRMS are in in Appendix I.    
3.7. Work Towards a Novel Tri-Modal Imaging Agent for OMI-PET-MRI 
 There are few references of tri-modal imaging agents in literature.  This may be 
due to the fact that current medical instrumentation does not allow for the simultaneous 
acquisition of data using three different methods.  However, one of the goals of this 
research project was to create a novel tri-modal imaging agent that could potentially be 
used in OMI-PET-MRI when technology allows for it.  To achieve this, the same dual-
modal imaging agent that was synthesized in Scheme 7 (for PET-MRI) was to be 
combined with the NHS of the dye created in Scheme 4 (for OMI).  This would contain 
three different imaging moieties, each useful for a different application, making it a tri-
modal imaging agent.  The reaction in which the previously described PET-MRI imaging 
module (after removing the Fmoc group) and the NHS ester of the Cy 5.5 3S dye were 
combined is given in Scheme 13. 
 In this final reaction, the crude reaction mixture was carried out, and quenched 
two ways, with water and with butyl amine solution, then and assayed by LC-MS.  
Although the un-optimized reaction mixture contained five products, all of which 
contained the Cy5.5 dye as shown by the UV-Vis trace of each and a single wavelength 
chromatogram at 684 nm, one of these products, with a retention time of 4.89 minutes, 
was determined to be the product.  The positive and negative ion mass spectra showing 
half mass [M-2H]2-/2 in negative ion (ESI-) and third mass [M+3H]3-/3 in positive ion 
(ESI+), along with an expanded spectra showing the gadolinium isotope pattern, and along 
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with the expected wavelength for Cy5.5 clearly prove that the structure had been 
confirmed. This data is shown in the experimental section under the synthesis of 
Compound 18 as shown in Scheme 13.  
 
Scheme 13. Synthesis of Tri-Modal Imaging Molecule for OMI-PET-MRI, F-dK(Cy 5.5 3S)-
dK(Gd-DOTA)-K(Gd-DOTA)-NH2 (18) 
Due to time constraints, and notably the inability to return to lab in March 2020 
due to the dire global health situation which required social distancing, this crude reaction 
mixture was precipitated and remained in the freezer for the duration of the semester.  
However, the project was taken to the point where a future student could carry on 
this synthesis to completion.  The crude reaction mixture could be purified by preparative 
HPLC, then the Fmoc group would be deprotected followed by convergent addition of 
the either with a targeting group and linker used in this research: c(RGDyK)-DSS and 







 The modular synthetic method used in this project has proven to be useful and 
practical in the synthesis of multi-modal TMIAs.  This research project demonstrated the 
complete synthesis of four (4) novel TMIAs that could be used in dual-modal molecular 
imaging. Studies towards tri-modal and other multi-modal imaging agents are still 
ongoing, but current results show much promise for the feasibility of these compounds. 
 The synthesis of the compounds in which lanthanum is used as a placeholder for a 
radioactive metal, such as copper-64 or gallium-68, has proved to be a sufficient method.  
It is important that the final transmetalation step was worked out in this project, as this is 
the step in which the compound becomes useful for PET imaging.  This has been an 
ongoing project in the molecular imaging laboratory and it is encouraging that the full 
synthesis of these molecules was finally worked out. 
 Although these compounds have been successfully synthesized and characterized 
using HPLC-MS and HRMS, their effectiveness as imaging agents still needs to be 
tested.  Collaborations and plans for both in vivo and in vitro testing have been set up and 
will take place in the future.  This will allow our group to determine if it is feasible to use 
these compounds as TMIAs. 
 The results and data from this project not only show the synthesis of many novel 
TMIAs, but also presents the framework for synthesizing other multi-modal imaging 
agents using a modular synthetic approach.  Using amino acids with imaging agents 
attached to their side chains is a method that has proven to be effective through this 
research project and this method could be used in a variety of different imaging 
applications.  
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5. Experimental Procedures 
Chemicals were purchased from Acros Organics (Morris Plains, NY), Alfa Aesar (Ward 
Hill, MA), Sigma Aldrich (St. Louis, MO), TCI (Tokyo, Japan), and VWR (Randnor, 
PA) and were used as received unless stated otherwise.  All chemicals were either 
American Chemical Society (ACS) or HPLC grade.  Amino acid starting materials were 
purchased from Bachem (Bubendorf, Switzerland) and Chem-Impex International Inc. 
(Wood Dale, IL).  DOTA was purchased from Macrocyclics (Houston, TX). 
 
The HPLC instrument used was an Agilent 1100 with Diode Array Detector and for LC-
MS a Waters 2695 Alliance HPLC with a Waters 2998 Diode Array Detector and a 
Waters 3100 SQ Mass Spectrometer was used.  For HPLC the columns used were: an 
Agilent XDB C18 column, with dimensions of 3 mm x 100 mm or a Waters XBridge 
C18 column 50 mm x 3 mm and 3µ particle size.  Mass spectra from this instrument were 
recorded at unit resolution with positive and negative switching mode at 35 or 50 V cone 
voltages.  The flow rate for HPLC-MS was 0.5 mL/min.  All aqueous mobile phases for 
HPLC are 0.01M ammonium acetate unless otherwise noted. Preparative HPLC (prep-
HPLC) was carried out with a Waters 600E system controller, and Waters 600 multi-
solvent delivery system using a 30 mL/min flow rate.   
 
For SPE purification, a 20 g C-18 Sep-pack Varian Mega Bond Elut (20CC/5GRM) SPE 
cartridge was utilized for DCL (7) and Gd/La DOTA compounds, and the DOTA 
transmetalations utilized a Varian Bond Elut (C18, 12CC/2GRM) SPE cartridge.  
 
Transmetalation studies were monitored using a Shimadzu UHPLC-MS with a Nexera 
X2 UHPLC, and LCMS-2020 Mass Spectrometer. A Phenomenex Kinetex EVO C18 150 
x 2.1mm column with a 1.7µ particle size was used to assay all transmetalation reactions 
and purifications. The flow rate for UHPLC-MS was 0.4 mL/min. The aqueous mobile 
phase for UHPLC was 0.01M ammonium acetate and organic phase was methanol with 
the gradient described below and in each experimental section.   
  
Aqueous mobile phases for SPE are not buffered unless otherwise noted. The SPE 
cartridges were conditioned with their respective organic solvent, then pure DI H2O, then 
equilibrated with the initial gradient concentration. Gradients were performed in 5% 
increments with 3-10 mL fractions each unless otherwise noted.  
 
High resolution mass spectra (HRMS) were obtained on a Waters Synapt G2Si (School 
of Chemical Sciences, University of Illinois at Urbana-Champaign) using the following 
parameters: Flow injection at flow rate of 0.1 ml/min, H2O/ACN/0.1% Formic Acid, 
positive and negative mode ESI, Cone voltage = 25, capillary voltage = 3.0, ion source 
temperature = - 100°C, desolation temperature  =180’C,  nebulizing gas (N2) flow = 200 





F-dK(La-DOTA)-OH (1) DOTA (493.6 mg, 0.96 mmol, Macrocyclics) was stirred into 
suspension in a solution of NMM (1124.1 mg, 11.1 mmol) in anhydrous DMF (50 mL). 
This solution was heated briefly to promote solvation, then allowed to cool back to room 
temperature. A solution of TBTU (356.9 mg, 1.11 mmol) in DMF (10 mL) was added to 
the reaction flask over 30 minutes with the use of a syringe pump, followed by the 
addition of a solution of Fmoc-dLys(H)-OH (300.0 mg, 0.74 mmol) in the same manner. 
Immediately following the dropwise addition of this reagent, La(NO3) (481.5 mg, 1.48 
mmol) was added to the reaction flask as a crystalline salt. The reaction was stirred 
another 25 minutes.  Crude product was precipitated from the solution by the addition of 
ethyl ether and isolated by decanting the organic solvent after centrifugation. Purification 
by SPE (ACN/H2O, 10-60%) yielded the desired product. Yield: 47.4 mg (7%). MS (HR, 
ESI) calc. for C37H47LaN6O11 890.23663, found 891.2431 [M+H]+. 
 
F-K(Gd-DOTA)-NH2 (2) Commercially-available DOTA (692.3 mg, 1.35 mmol) was 
stirred into suspension in a solution of NMM (1576.6 mg, 15.6 mmol) in anhydrous DMF 
(50 mL). This solution was heated briefly to promote solvation, then allowed to cool back 
to room temperature. A solution of TBTU (667.32 mg, 2.08 mmol) in DMF (10 mL) was 
added to the reaction flask over 30 minutes with the use of a syringe pump, followed by 
the addition of a solution of Fmoc-Lys(H)-NH2 (500.0 mg, 1.04 mmol) in the same 
manner. Immediately following the dropwise addition of this reagent, Gd(OAc)3 (844.6 
mg, 2.08 mmol) was added to the reaction flask as a crystalline salt. The reaction was 
stirred another 25 minutes.  Crude product was precipitated from the solution by the 
addition of ethyl ether and isolated by decanting the organic solvent after centrifugation. 
Purification by SPE (ACN/H2O, 10-60%) yielded the desired product. Yield: 105.2 mg 
(11%). MS (HR, ESI) calc. for C37H48GdN7O10 908.27037, found 909.2765 [M+H]+. 
 
F-dK(Gd-DOTA)-OH (3) Commercially-available DOTA (493.8 mg, 0.964 mmol) was 
stirred into suspension in a solution of NMM (1124.5 mg, 11.1 mmol) in anhydrous DMF 
(50 mL). This solution was heated briefly to promote solvation, then allowed to cool back 
to room temperature. A solution of TBTU (357.0 mg, 1.11 mmol) in DMF (10 mL) was 
added to the reaction flask over 30 minutes with the use of a syringe pump, followed by 
the addition of a solution of Fmoc-dLys(H)-OH (300.1 mg, 0.741 mmol) in the same 
manner. Immediately following the dropwise addition of this reagent, Gd(OAc)3 (495.7 
mg, 1.48 mmol) was added to the reaction flask as a crystalline salt. The reaction was 
stirred another 25 minutes.  Crude product was precipitated from the solution by the 
addition of ethyl ether and isolated by decanting the organic solvent after centrifugation. 
Purification by SPE (ACN/H2O, 10-60%) yielded the desired product. Yield: 146.8 mg 
(22%). MS (HR, ESI) calc. for C37H47GdN6O11 909.25439, found 910.2621 [M+H]+. 
 
F-dK(Cy5.5 3S)-OH (4) Commercially available Fmoc-dLys(H)-OH (28.0 mg, 0.0692 
mmol) was dissolved in NMP (3 mL) the solution was cooled to 0°C.  To this solution 
was added DIPA (89.37 mg, 0.692 mmol) followed by the Cy 5.5 3S-NHS ester.  The 
reaction was brought to room temperature and was stirred for 1 hour.  Crude product was 
precipitated by the addition of diethyl ether, and the organic layer was decanted after 
centrifugation.  Pure product was obtained by preparatory HPLC (ACN/0.01% AmAc, 5-
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80%).  Fractions containing pure product were collected, concentrated by rotary 
evaporation, and freeze dried. Yield: 14.8 mg, 35%.  
 
H-K(Gd-DOTA)-NH2 (5) Compound 2 (31.1 mg, 0.034 mmol) was dissolved in 
anhydrous DMF (5 mL). DEA (50.1 mg, 0.69 mmol) was added to this solution. The 
reaction stirred under inert atmosphere one hour. Crude product was precipitated by 
addition of ethyl ether to the reaction solution, and organic solvent was decanted after 
centrifugation. This process was repeated with ethyl acetate.  Product was dried under 
vacuum. Yield: 23.5 mg (100%). MS (HR, ESI) calc. for C22H37GdN7O8 686.20229, 
found 687.2101 [M+H]+.   
 
F-dK(Cy5.5 3S)-K(Gd-DOTA)-NH2 (6) Compound 4 (10.0 mg, 8.23x10-3 mmol) was 
dissolved in DMF (10 mL) and to this solution was added DIPA (10.63 mg 0.0823 mmol) 
and TSTU (4.95 mg, 0.0165 mmol).  This reaction stirred under argon 1 hour and was 
monitored by HPLC-MS after treating a sample with 0.1% aqueous butylamine.  Upon 
completion of this portion of the reaction, crude intermediate product was precipitated by 
the addition of EtOAc and diethyl ether, and after centrifugation the organic layer was 
decanted and the crude solid dried under argon.  Compound 5 (7.34 mg, 0.0107 mmol) 
was dissolved in DMSO (1 mL).  To this solution was added DIPA (10.63 mg, 0.0823 
mmol), followed by the previously isolated product which had been reconstituted in DMF 
(5 mL).  The reaction ran for 2.5 hours. Crude product was precipitated by the addition of 
ethyl ether, and the organic layer was decanted after centrifugation. Pure product was 
obtained by SPE (MeOH/H2O, 10-65%). Fractions containing pure product were 
collected, concentrated by rotary evaporation, and freeze dried.  Yield: 15.5 mg, 100%.  
MS (HR, ESI) calc. for C86H106GdN11O21S3 1882.59624, found 942.3064 [M+2H]2+/2. 
 
H-dK(Cy5.5 3S)-K(Gd-DOTA)-NH2 (7) Compound 6 (15.0 mg , 7.96x10-3) was 
dissolved in DMF (3 mL) and to this solution was added diethylamine (11.7 mg, 0.159 
mmol).  Reaction ran for 3 hours.  Crude product was precipitated by the addition of 
diethyl ether.  This was centrifuged and the organic layer decanted; the crude solid was 
triturated with EtOAc to remove Fmoc byproduct, and was again centrifuged and the 
organic layer, decanted.  Yield: 13.2 mg, 100%.  MS (HR, ESI) calc. for 
C71H96GdN11O19S3 1660.52816, found 831.2723 [M+2H]2+/2. 
 
DCL-DSS-dK(Cy5.5 3S)-K(Gd-DOTA)-NH2 (8) Compound 7 (13.2 mg, 7.95x10-3 
mmol) was dissolved in DMF (2 mL) and to this solution was added TEA (20.1 mg, 
0.199 mmol).  DCL-DSS (9.09 mg, 0.0159 mmol) was dissolved in DMSO (0.2 mL) and 
added to the reaction.  Reaction was left to stir.  After 2.5 hours, TEA (12.1 mg, 0.119 
mmol) was added. After 4 hours, additional TEA was added (8.0 mg, 0.0796 mmol).  The 
reaction was left to react for 12 hours.  DCL-DSS (18.18 mg, 0.0318 mmol) was added 
after being dissolved in DMSO (0.462 mL).  Crude product was precipitated by the 
addition of ethyl ether, and the organic layer was decanted after centrifugation. Pure 
product was obtained by preparatory HPLC (ACN/H2O, 5-100%). Fractions containing 
pure product were collected, concentrated by rotary evaporation, and freeze dried.  Yield: 
11.3 mg, 67%.  MS (HR, ESI) calc. for C91H127GdN14O28S3 2117.73419, found 
1059.8750 [M+2H]2+/2. 
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F-dK(La-DOTA)-K(Gd-DOTA)-NH2 (9) Compound 1 (32.6 mg, 3.66x10-2 mmol) was 
dissolved in NMP (2.5 mL) and to this solution was added DIPA (47.3 mg, 0.366 mmol) 
and TSTU (22.0 mg, 7.32 x10-2 mmol). This reaction stirred under argon for 1 hour and 
was monitored by HPLC-MS after treating a sample with 0.1% aqueous butylamine. 
Upon completion of this portion of the reaction, crude intermediate product was 
precipitated by the addition of EtOAc and diethyl ether, and after centrifugation the 
organic layer was decanted and the crude solid dried briefly under argon. Compound 5 
(41.4 mg, 6.04x10-2 mmol) was dissolved in 1.5 mL DMSO. To this solution was added 
triethylamine (74.04 mg, 0.732 mmol), followed by the previously isolated crude product 
which had been reconstituted in NMP (2 mL). This reaction ran for 1 hour. Crude product 
was precipitated by the addition of ethyl ether, and the organic layer was decanted after 
centrifugation. Pure product was obtained by SPE (ACN/H2O, 10-60%). Fractions 
containing pure product were collected, concentrated by rotary evaporation, and freeze 
dried. Yield: 18.8 mg, 33%. MS (HR, ESI) calc. for C59H83GdLaN13O18 1558.42836, 
found 780.223 [M+2H]2+/2. 
 
H-dK(La-DOTA)-K(Gd-DOTA)-NH2 (10) Compound 9 (18.8 mg, 1.21x10-2 mmol) 
was dissolved in DMF (3 mL) followed by the addition of diethylamine (17.6 mg, 0.24 
mmol). Reaction ran for 1 hour. Crude product was precipitated by the addition of diethyl 
ether. This was centrifuged and the organic layer decanted; the crude solid was triturated 
with EtOAc to remove Fmoc byproduct, and was again centrifuged and the organic layer, 
decanted. Yield: 14.8 mg, 92%. MS (HR, ESI) calc. for C44H73GdLaN13O16 1336.36028, 
found 1337.369 [M+H]+. 
 
c(RGDyK)-DSS (11) Commercially purchased c(RGDyK) (6.97 mg, 0.0112 mmol) was 
dissolved into DMF (1 mL) and to this solution was added TEA (5.69 mg, 0.0562 mmol).  
This solution was added dropwise to a separate solution of DSS (4.56 mg, 0.0124 mmol) 
that was previously dissolved in DMF (1 mL).  Yield: 9.82 mg 100%.  MS (HR, ESI) 
calc. for C39H56N10O13 872.40283, found 873.4103 [M+H]+. 
 
c(RGDyK)-DSS-dK(La-DOTA)-K(Gd-DOTA)-NH2 (12) Compound 10 (5.00 mg, 
3.74x10-3 mmol) was dissolved in DMF (2 mL) and to this solution was added TEA (9.47 
mg, 0.0935 mmol).  Compound 11 (6.53 mg, 7.4x10-3 mmol) was dissolved in DMSO (1 
mL) and added to the reaction.  Reaction was left to stir.  After 1 hour, TEA (3.79 mg, 
0.0374 mmol) was added.  After 3 hours, additional TEA (3.79 mg, 0.0374 mmol) was 
added.  The reaction was left to reaction for 12 hours following the addition of DMSO (1 
mL).  Butylamine (2.19 mg, 0.0299 mmol) was added to the reaction to quench 
remaining compound 11. Crude product was precipitated by the addition of ethyl ether, 
and the organic layer was decanted after centrifugation.  Yield: 4.1 mg, 52%.  MS (HR, 
ESI) calc. for C79H124GdLaN22O26 2093.736169, found 1047.8777 [M+2H]2+/2. 
 
c(RGDyK)-DSS-dK(Cu-DOTA)-K(Gd-DOTA)-NH2 (13) Compound 12 (0.91 mg, 
4.35x10-4 mmol) was dissolved in aqueous TFA (0.2 M, 1 mL).  This solution was stirred 
and monitored via UPLC-MS until all of the lanthanum was displaced.  After 4 days, 
CuSO4 (0.69 mg, 4.35x10-6 mmol) was dissolved in H2O (0.2 mL) and added to the 
solution.  The reaction was stirred for 30 min.  Additional CuSO4 (1.4 mg, 8.70x10-6 
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mmol) was added to the reaction in H2O (0.2 mL).  Reaction was stirred for an additional 
30 min.  Sodium bicarbonate (0.1 M) was added dropwise until the solution was neutral.  
Pure product was obtained by SPE (ACN/0.05% aq. TFA, 2-25%). Fractions containing 
pure product were collected, concentrated by rotary evaporation, and freeze dried.  Yield: 
0.68 mg, 77%. MS (HR, ESI) calc. for C79H124CuGdN22O26 2017.75832, found 673.9305 
[M+3H]3+/3. 
 
c(RGDyK)-DSS-dK(Ga-DOTA)-K(Gd-DOTA)-NH2 (14) Compound 12 (0.88 mg, 
4.20x10-4 mmol) was dissolved in aqueous TFA (0.2 M, 1 mL).  This solution was stirred 
and monitored via UPLC-MS until all of the lanthanum was displaced.  After 24 hours, 
this compound was concentrated by rotary evaporation.  The compound was dissolved in 
distilled H2O (1 mL).  Ga(NO3)3•H2O (3.21 mg, 0.0126 mmol) was dissolved in H2O (0.2 
mL) and added to the solution.  The reaction was stirred for 1 hour.  Sodium bicarbonate 
(0.1 M) was added dropwise until the solution was neutral.  Pure product was obtained by 
SPE (ACN/0.05% aq. TFA, 4-25%).  Fractions containing pure product were collected, 
concentrated by rotary evaporation and freeze dried.  Yield: 0.85 mg, 100%.  MS (HR, 
ESI) calc. for C79H124GaGdN22O26 2023.75429, found 675.5933 [M+3H]3+/3. 
 
F-dK(Gd-DOTA)-K(Gd-DOTA)-NH2 (15) Compound 3 (41.7 mg, 0.0459 mmol) was 
dissolved in NMP (5 mL) and to this solution was added DIPA (118.6 mg, 0.917 mmol) 
and TSTU (27.6 mg, 0.0917 mmol).  This reaction stirred under argon 1 hour and was 
monitored by HPLC-MS after treating a sample with 0.1% aqueous butylamine.  Upon 
completion of this portion of the reaction, crude intermediate product was precipitated by 
the addition of EtOAc and diethyl ether, and after centrifugation the organic layer was 
decanted and the crude solid dried briefly under argon.  Compound 5 (31.47 mg, 0.0459 
mmol) was dissolved in NMP (1 mL).  To this solution was added DIPA (118.59 mg, 
0.918 mmol), followed by the previously isolated product which had been reconstituted 
in NMP (1 mL).  The reaction ran for 3 hours. Crude product was precipitated by the 
addition of ethyl ether, and the organic layer was decanted after centrifugation. Pure 
product was obtained by SPE (ACN/H2O, 10-60%). Fractions containing pure product 
were collected, concentrated by rotary evaporation, and freeze dried. Yield: 23.6 mg, 
33%. MS (HR, ESI) calc. for C59H83Gd2N13O18 1577.44501, found 789.7323 [M+2H]2+/2. 
 
H-dK(Gd-DOTA)-K(Gd-DOTA)-NH2 (16) Compound 15 (23.6 mg, 0.015 mmol) was 
dissolved in NMP (2 mL) followed by the addition of diethylamine (32.8 mg, 0.449 
mmol).  Reaction ran one hour.  Crude product was precipitated by the addition of diethyl 
ether.  This was centrifuged and the organic layer decanted; the crude solid was triturated 
with EtOAc to remove Fmoc byproduct, and was again centrifuged and the organic layer, 
decanted. Yield: 20.3 mg, 100%. MS (HR, ESI) calc. for C44H73Gd2N13O16 1355.37693, 
found 1356.3833 [M+H]+. 
 
c(RGDyK)-DSS-dK(Gd-DOTA)-K(Gd-DOTA)-NH2 (17) Compound 16 (1.27 mg, 
9.35x10-4 mmol) was dissolved in DMF (2 mL) and to this solution was added TEA (2.36 
mg, 0.0234 mmol).  Compound 11 (1.63 mg, 1.87x10-3 mmol) was dissolved in DMSO 
(0.4 mL) and added to the reaction.  The reaction was set to stir.  After 1 hour, TEA (4.36 
mg, 0.043 mmol) was added to increase the basicity of the solution. Additional 16 (1.27 
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mg, 9.35x10-4 mmol) was added.  It was determined via HPLC-MS that the coupling 
reaction was not progressing.  DSS (4.19 mg, 0.0114 mmol) was added to the reaction 
mixture.  The reaction was heated to 40°C and stirred for 24 hours.  Remaining DSS was 
removed after precipitating solid by the addition of ethyl ether, and the organic layer was 
decanted after centrifugation. This process was repeated with cold ethyl acetate, followed 
by warm ethyl acetate.  The solid was dried under argon.  The following day, the solid 
was dissolved in a 1:1 solution of DMSO and DMF (2 mL).  c(RGDyK) (6.41 mg, 0.0103 
mmol) was added along with TEA (26.15 mg, 0.258 mmol).  The solution was stirred for 
3 hours.  Upon completion of the reaction, crude product was precipitated by the addition 
of EtOAc and diethyl ether, and after centrifugation the organic layer was decanted and 
the crude solid dried under argon.  Pure product was obtained by SPE (ACN/0.05% aq. 
TFA, 4-25%).  Fractions containing pure product were collected, concentrated by rotary 
evaporation and freeze dried.  Yield: 14.1 mg, 65%.  MS (HR, ESI) calc. for 
C79H124CuGdN22O26 2017.75832, found 673.9305 [M+3H]3+/3. 
 
F-dK(Cy5.5 3S)-dK(La-DOTA)-K(Gd-DOTA)-NH2 (18) Compound 4 (14.8 mg, 
1.22x10-2 mmol) was dissolved in DMF (10 mL) and to this solution was added DIPA 
(15.74 mg 0.122 mmol) and TSTU (7.33 mg, 0.0244 mmol).  This reaction stirred under 
argon 1 hour and was monitored by HPLC-MS after treating a sample with 0.1% aqueous 
butylamine.  Upon completion of this portion of the reaction, crude intermediate product 
was precipitated by the addition of EtOAc and diethyl ether, and after centrifugation the 
organic layer was decanted and the crude solid dried briefly under argon.  Compound 10 
(4.79 mg, 3.58x10-3 mmol) was dissolved in DMSO (0.5 mL).  To this solution was 
added TEA (7.25 mg, 0.0717 mmol), followed by the previously isolated product which 
had been reconstituted in NMP (2 mL).  The reaction ran for 1 hour. Crude product was 
precipitated by the addition of ethyl ether, and the organic layer was decanted after 
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Appendix I. HPLC-MS and HRMS Results 
Compound 1 F-dK(La-DOTA)-OH 
 
Single wavelength chromatogram of 1 at 263 nm for crude reaction mixture 
 
UV-Vis of 1 spectrum at 1.6 min with characteristic peak at 263 nm for Fmoc protecting group 
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HRMS of pure 1 product, 891.2431 m/z [M+H]+  
 71 
 
Compound 2 F-K(Gd-DOTA)-NH2 
 
Single wavelength chromatogram of 2 at 263 nm for crude reaction mixture 
 
UV-Vis spectrum of 2 at 3.6 min with characteristic peak at 263 nm for Fmoc protecting group 
 
Mass spectrum of 2 at 3.6 min, 909.96 m/z [M+H]+ 
19_07_03_NS_F-K(DOTA-Gd)-NH _b
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Expanded parent ion from spectrum above, displaying Gd isotope pattern of 2 
 



















Compound 3 F-dK(Gd-DOTA)-OH 
 
Single wavelength chromatogram of 3 at 263 nm for crude reaction mixture 
 
UV-Vis spectrum of 3 at 1.6 min with characteristic peak at 263 nm for Fmoc protecting group 
 
Mass spectrum of 3 at 1.6 min, 909.51 m/z [M+H]+ 
19_11_14_NS_F-dK(DOTA-Gd)-OH_monitor_1
Time













































798.89 1084.92 1260.79 1447.88
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Expanded parent ion from spectrum above, demonstrating Gd isotope pattern of 3 
 
















Compound 4 F-dK(Cy5.5 3S)-OH 
 
Single wavelength chromatogram of 4 at 680 nm for pure product 
 
UV-Vis spectrum of 4 at 5.3 min with characteristic peak around 684 nm for Cy 5.5 dye 
 





















































Compound 5 H-K(Gd-DOTA)-NH2 
 
  
UV-Vis spectrum of 5 at 1.1 min, demonstrating lack of characteristic Fmoc absorption 
 
XIC for 5 of mass range 685 to 687 m/z 
 
Mass spectrum of 5 at 1.1 min, 685.4 m/z [M+H]+ 
19_12_04_NS_H-K(DOTA-Gd)-NH2_1hr_monitor_2
nm





































783.28 843.45 971.74 1072.08 1182.72
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Expanded parent ion of 5 from spectrum above, displaying Gd isotope pattern 
 
HRMS of pure 5 product displaying Gd isotope pattern, 687.2101 m/z [M+H]+ 
19_12_04_NS_H-K(DOTA-Gd)-NH2_1hr_monitor_2
m/z












708.38697.48 711.39 736.34729.02 745.10
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Compound 6 F-dK(Cy5.5 3S)-K(Gd-DOTA)-NH2 
 
Single wavelength chromatogram of 6 at 680 nm for purified product 
 
UV-Vis spectrum of 6 at 3.4 min with characteristic peak around 683 nm for Cy 5.5 dye 
 
Mass spectrum of 6 at 3.4 min, 943.32 m/z [M+2H]2+/2 
F-dK(Cy55)-K(DOTA-Gd)-NH2_55
Time















































Expanded parent ion of 6 from spectrum above, displaying Gd isotope pattern 
 



















Compound 7 H-dK(Cy5.5 3S)-K(Gd-DOTA)-NH2 
 
Single wavelength chromatogram of 7 at 680 nm showing product 
 
UV-Vis spectrum of 7 at 1.8 min with characteristic peak around 683 nm for Cy 5.5 dye 
 
Mass spectrum of 7 at 1.8 min, 831.52 m/z [M+2H]2+/2 
H-dK(Cy55)-K(DOTA-G )-NH2_60mins_monitor_c
Time











































Expanded parent ion of 7 from spectrum above, demonstrating Gd isotope pattern 
 


















Compound 8 DCL-DSS-dK(Cy5.5 3S)-K(Gd-DOTA)-NH2 
 
Single wavelength chromatogram of 8 at 680 nm for pure product 
 
UV-Vis spectrum of 8 at 2.9 min with characteristic peak around 683 nm for Cy 5.5 dye 
 

































Mass spectrum of 8 at 2.9 min, 1058 m/z [M-2H]2-, 705 m/z [M-3H]3-/3 
 
HRMS of pure 8 product showing Gd isotope pattern, 1059.8750 m/z [M+2H]2+/2 















Compound 9 F-dK(La-DOTA)-K(Gd-DOTA)-NH2 
 
Single wavelength chromatogram of 9 on UPLC-MS at 263 nm for pure product 
 
UV-Vis spectrum of 9 at 3.3 min with characteristic peak at 265 nm for Fmoc protecting group 




































Mass spectrum of 9 at 3.3 min, 1560 m/z [M+H]+, 780 m/z [M+2H]2+/2 
 
HRMS of pure 9 product showing Gd isotope pattern 780.2230 m/z [M+2H]2+ 



















Compound 10 H-dK(La-DOTA)-K(Gd-DOTA)-NH2 
 
UV-Vis spectrum of 10 at 0.5 min, demonstrating lack of characteristic Fmoc absorption 
 
XIC of crude reaction mixture for 10 showing conversion of starting material (780 m/z) to product (669 
m/z) 


















































Mass spectrum of 10 at 0.5 min, 669 m/z [M+2H]2+/2 
 
HRMS of pure 10 product displaying Gd isotope pattern 1337.3690 m/z [M+H]+ 















Compound 11 c(RGDyK)-DSS 
 
XIC of mass range 832 to 833 m/z for compound 11 
 
Mass spectrum of 11 in 0.1% aq. butylamine at 3.0 min, 832.19 m/z buylamine adduct of product, 416.83 
half mass of butylamine adduct 
19_09_23_NS_c(RGDyK)-DSS_BAquench_2
Time





























HRMS of pure 11 product, 873.4103 m/z [M+H]+ 
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Compound 12 c(RGDyK)-DSS-dK(La-DOTA)-K(Gd-DOTA)-NH2 
 
XIC of mass range 1047 to 1050 m/z for compound 12 
 
Mass spectrum of 12 at 3.8 min, 1046.96 m/z [M+2H]2+, 698.63 m/z [M+3H]3+/3 
 













































HRMS of pure 12 product displaying Gd isotope pattern, 1047.8730 m/z [M+2H]2+/2 
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Compound 13 c(RGDyK)-DSS-dK(Cu-DOTA)-K(Gd-DOTA)-NH2 
 
XIC of mass 674 m/z for compound 13 
 
Mass spectrum of 13 at 1.4 min, 1011 m/z [M+2H]2+, 674 m/z [M+3H]3+/3 






























HRMS of pure 13 product displaying Gd isotope pattern, 673.5975 m/z [M+3H]3+/3  
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Compound 14 c(RGDyK)-dK(Ga-DOTA)-K(Gd-DOTA)-NH2 
 
XIC of mass 676 m/z for compound 14 
 
Mass spectrum of 14 at 0.9 min, 1014 m/z [M+2H]2+, 676 m/z [M+3H]3+/3 





































Compound 15 F-dK(Gd-DOTA)-K(Gd-DOTA)-NH2 
 
Single wavelength chromatogram of 15 at 263 nm for crude reaction mixture 
 
UV-Vis spectrum of 15 at 2.9 min with characteristic peak around 263 nm for Fmoc protecting group 
 
Mass spectrum of 15 at 2.9 min, 1577.97 m/z [M+H]+, 789.71 m/z [M+2H]2+/2 
19_12_05_NS_F-dK(DOTA-G )-K(DOTA-Gd)-NH2_3hr_BA
Time

















































Expanded parent ion of 15 from spectrum above, displaying Gd isotope pattern 
 
HRMS of pure 15 product displaying Gd isotope pattern,789.7323 m/z [M+2H]2+  
19_12_05_NS_F-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_3hr_BA
m/z

















Compound 16 H-dK(Gd-DOTA)-K(Gd-DOTA)-NH2 
 
UV-Vis spectrum of 16 at 1.5 min, demonstrating lack of characteristic Fmoc absorption 
 
XIC of mass range 678 to 680 m/z for compound 16 
 
Mass spectrum of 16 at 1.5 min, 678.19 m/z [M+2H]2+/2 
19_12_09_NS_H-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_60min
nm












































Expanded parent ion from spectrum above of 16, displaying Gd isotope pattern 
 



















Compound 17 c(RGDyK)-DSS-dK(Gd-DOTA)-K(Gd-DOTA)-NH2 
 
XIC of mass range 1057 to 1059 m/z for compound 17 
 
Mass spectrum of 17 at 1.0 min, 1057.46 m/z [M+2H]2+, 705.03 m/z [M+3H]3+/3 
 

























































HRMS of pure 17 product displaying Gd isotope pattern, 1057.3828 m/z [M+2H]2+/2 
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Compound 18 F-dK(Cy5.5 3S)-dK(La-DOTA)-K(Gd-DOTA)-NH2 
 
Single wavelength chromatogram of 18 at 684 nm showing product in crude reaction mixture.  The product 
18 is the peak at 4.89 minutes.   
 
 
UV-Vis spectrum of 18 at 4.9 min, showing absorption peak for Cy5.5 dye 
 
XIC of compound 18, the product is the peak at 4.88 min 
20_02_20_NS_F-K(Cy55)-K(DOTA-La)-K(DOTA-Gd)-NH2_25hr_mon_b
Time



























































ESI- mass spectra of product peak at 4.9 min at showing product 18 at 1265.73, [M+2H]2+/2 
 
Expanded region of ESI- mass spectra of 18 showing Gd isotope pattern 
 

























































Mass spectrum of 18 at 4.8 min, 845.86 m/z [M+3H]3+ displaying Gd isotope pattern. This result taken with 
















854.05 867.46 870.63 878.08 883.65
